826P - Description of a subpopulation of renal patients with long-term progression free survival (PFS) with sunitinib: a SOG_GU experience

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anticancer agents
Renal Cell Cancer
Biological therapy
Presenter Emilio Esteban
Authors E. Esteban1, L. Anton-Aparicio2, S. Vazquez3, U. Anido4, F.J. Afonso5, O. Fernandez6, M. Lazaro7, L. Santomé8, M. Ramos Vazquez9
  • 1Hospital Universitario Central de Asturias, Oviedo/ES
  • 2Medical Oncology, Complejo Hospitalario A Coruña, A Coruña/ES
  • 3Oncology, Hospital Universitario Lucus Augusti, 27003 - Lugo/ES
  • 4Dept. Of Medical Oncology, Complejo Hospitalario Universitario de Santiagode Compostela SERGAS, ES-15706 - Santiago de Compostela/ES
  • 5Medical Oncology, Complejo Hospitalario Arquitecto Marcide, Ferrol/ES
  • 6Medical Oncology, Complexo Hospitario de Ourense, 32005 - Ourense/ES
  • 7Oncoloxia Médica, Complexo Hospitalario Universitario de Vigo, 36200 - Vigo/ES
  • 8Medical Oncology, Hospital Povisa de Vigo, Vigo/ES
  • 9Medical Oncology, Centro Oncológico de Galicia, 15009 - A Coruña/ES


A multicenter retrospective analysis was performed in patients with metastatic RCC who achieved long-term progression-free survival (PFS) defined as ≥18 months during treatment with sunitinib. Forty six patients (87% male) treated with sunitinib in first (74%) or subsequent lines were included. Median age was 59 years and most common histology was clear cell (93,5%); 89% had undergone prior nephrectomy, 28.3% were metastatic at diagnosis and 58.7% presented one site of metastasis, 28.3% two sites and 13% three or more sites. Twelve patients (26%) had bone metastases. Good, medium and poor prognosis (MKSCC) was presented in 30,4%, 67,4% and 2,2% of patients respectively. Five patients (11%) achieved a complete response (CR), 28 (61%) partial response (PR) and 13 (28.3%) a stable disease with 9 patients (69.2%) achieving stabilization for ≥25 months. Median duration of response was 22.7 months Median time from diagnosis to sunitinib treatment was 2.23 years and median duration of therapy was 27 months. At the time of analysis 37% were still on sunitinib. Median time from start Sunitinib until PR and CR was 4.7 and 12.1 months respectively. Median PFS in the first line setting was 35.4 months (IC95% = [27,52-43,28]) and 31.6 months (IC95% = [5,13-58,13]) in subsequent lines. Median overall survival was not reached at the time of analysis. Reasons for discontinuation were progressive disease (83%), toxicity (10.3%) and death (3.4%). Incidence of adverse events was as expected, with asthenia, hand food syndrome (HFS), hypertension (HTA) and mucositis as main toxicities. Efficacy results are described in the table. The emergence of drug related toxicities, the lack of bone metastasis and the fact of non being metastatic at the time of diagnosis were independenly associated with a trend towards an improvement in PFS (p = NS). A comparison with a population of Sunitinib refractory patients is already ongoing.

Median PFS Months (p = NS)
With vs. without HTA 44.8 vs. 31.10
With vs. without Asthenia 35.5 vs. 32.43
with vs. without HFS 44.8 vs. 31
with vs. without Hypothiroidism 47.4 vs. 43.66
with vs. without bone metastasis 31 vs. 37.5
with vs. without metastasis at diagnosis 32.43 vs. 37.50


E. Esteban: Compensated Consultant/Advisory role at Pfizer

All other authors have declared no conflicts of interest.